WFH/LinkedIn
Sep 18, 2025, 09:18
WFH Vice President Glenn Pierce on Slow Uptake and Industry Shifts in Hemophilia Gene Therapy
The World Federation of Hemophilia (WFH) posted on LinkedIn:
”WFH Vice President, Medical, Glenn Pierce, joins Zoey Becker in this week’s episode of The Top Line, to unpack the complex reality of Gene Therapy for hemophilia. Pierce discusses why the uptake remains slow, what led to some pharma companies exit and who risks being left behind in this evolving landscape.
Listen now.”
Stay updated with Hemostasis Today.
-
Apr 6, 2026, 04:46Ursula Porage Dona: Bringing the Bleeding Disorders Community Together at WFH 2026 with NNHF
-
Apr 6, 2026, 04:17Arun V J: How War Reshaped Blood Transfusion
-
Apr 6, 2026, 03:57Isabella Cieri: How TEG Is Transforming Vascular Surgery Care
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination
-
Apr 5, 2026, 18:05Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease
-
Apr 5, 2026, 17:45Matthew Walls: Recognising CAD PRS as a New ‘Risk Enhancing Factor’ in the 2026 ACC/AHA Guidelines
-
Apr 5, 2026, 17:44Philip A. Chan: Occasional Heavy Drinking Leads to 3 Times Higher Liver Fibrosis Risk in MASLD
-
Apr 5, 2026, 17:42Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia